clinical trial · NCT07349069
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.·phase3·recruiting·n = 4,800
Breast CancerHRS-8080 TabletsLetrozole tabletsTamoxifen Citrate Tablets
brief summary
The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with high-risk early breast cancer.
started
Mar 4, 2026
primary completion
Dec 1, 2030
completion
Jan 1, 2034
last updated
Mar 19, 2026
official title
A Randomized, Open-Label, Phase III Trial to Compare HRS-8080 Versus Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer Who Have Received at Least 2 Years of Standard Adjuvant Endocrine Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol